The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
7d
Live Science on MSNFDA approves 1st new class of opioid-free painkillers in over 20 yearsThe FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results